RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
NCT ID: NCT06823713
Last Updated: 2025-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2024-10-15
2028-11-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis
NCT06306781
Fast-track LiveR: Study for the Early Identification of Low-risk Patients After Partial Liver Resection by the LiMAx-test
NCT01785082
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
NCT06750276
Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis
NCT00004784
Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
NCT04048876
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
RTX001 is an autologous engineered macrophage cell therapy. It is made from a person's own cells. It uses a type of white blood cell called macrophages. These cells have been found to help improve liver function in participants with liver cirrhosis.
To produce RTX001, each study participant must first undergo steps that will allow us to collect white blood cells using a process called leukapheresis. Leukapheresis is a procedure in which white blood cells are separated from the collected blood using a specific machine. The collected white blood cells are sent to a manufacturing facility to make RTX001. As RTX001 is an autologous product, this means that it can only be given back to the same participant who donated the cells. The term "autologous macrophage" used in the study title refers to white blood cells (macrophages) coming from the same person's body (autologous).
The data in this study will be compared to the external control data from a Natural History Study called OPAL (NCT06380335) which is being conducted in a similar participant population from primarily the same study sites in the United Kingdom (UK) and EU.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RTX001
Following the manufacture of RTX001, participants will be assigned into one of two groups based on the compensation status of their cirrhosis at this time as follows:
* Stabilised Group: Participants who remain clinically stable, as assessed by the Investigator, since their qualifying decompensation event.
* Subsequent Decompensation Group: Participants who have had a further decompensation event following their leukapheresis and/or the RTX001 manufacturing process.
Treatment will be identical for both groups, and each participant will receive a maximum of four doses of RTX001 by intravenous infusion Patients in the Subsequent Decompensation Group need to have stabilised before receiving treatment.
RTX001
RTX001 is an autologous engineered regenerative macrophage cell therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RTX001
RTX001 is an autologous engineered regenerative macrophage cell therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient confirms willingness/ability to comply with all study procedures.
3. Diagnosis of liver cirrhosis based on at least one of:
1. Clinical and radiological features that correlate with a diagnosis of cirrhosis.
2. Transient elastography (Fibroscan) \>15 kPa.
3. Previous liver biopsy confirming histological features of cirrhosis.
4. Aetiology of liver disease of steatotic liver disease including MASLD or Met-ALD or ALD
a. Participants with alcohol-related liver disease (ALD or Met-ALD) only if they are confirmed to not be drinking alcohol above Met-ALD limits defined in this protocol. (N.B. No more than 34% of the total treated participants in this protocol will be ALD \[excludes Met-ALD\]).
5. Hospitalised as an inpatient for a recent major hepatic decompensation event including ascites, hepatic encephalopathy, variceal bleed, HRS-AKI or SBP, this being the only hospitalisation for an hepatic decompensation event hospitalisation within the last 6 months, and where recent is defined as within 6 weeks of hospital discharge.
6. Outpatient: Medically refractory ascites (ONLY), that recurs (i.e., second therapeutic LVP) within a 6-month period. Medically refractory ascites is defined by the repeated (≥2) need for LVP (i.e., therapeutic, not diagnostic) at least once per 8 weeks despite best medical attempts to control the ascites by sodium restriction and diuretic treatment, as confirmed by the Investigator. Onset is defined as the date of the second therapeutic LVP.
7. Confirmatory PEth alcohol test \<200 ng/ml
8. MELD score of 12-20 taken within two weeks of 'qualifying' decompensation event.
9. No known contradictions to filgrastim or leukapheresis procedure.
10. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
11. Willing and able to give signed informed consent, and if applicable assent.
Participants are excluded from the study if any of the following criteria apply:
Exclusion Criteria
1. any viral hepatitidies, or
2. autoimmune and cholestatic aetiologies including, but not limited to, primary biliary cholangitis and primary sclerosing cholangitis.
2. Acute liver disease in the absence of underlying liver cirrhosis, including, but not limited to, drug induced liver injury.
3. Any current organ failure requiring more than outpatient supportive care, and not associated with the participant's qualifying hepatic decompensation event.
4. Known splenomegaly ≥16 cm.
5. Thrombocytopenia \<50×109/L.
6. Presence or suspicion of any of the following co-morbidities:
1. History of liver transplantation or other organ transplant.
2. ACLF.
3. Sepsis (with positive microbial cultures) or as defined by the Principal Investigator, unless stable and is at least 4 weeks after having completed a full course of IV antibiotics.
4. Known human immunodeficiency virus.
5. Known syphilis.
6. Known human T-lymphotropic virus 1.
7. Pulmonary embolism.
8. Hepatocellular carcinoma, or any active malignant disease within the last five years, (excluding non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, benign polyps etc.).
9. Co-hepatic morbidities e.g., portal vein thrombosis.
10. Participants with hepatic hydrothorax are excluded unless it is a small hydrothorax, not clinically apparent, that is detected incidentally by radiologic evaluation that does not require clinical intervention.
11. Chronic renal impairment (on dialysis) or unresolved AKI.
12. Acute or chronic heart failure (New York Heart Association Grade III/IV).
13. Porto-pulmonary hypertension.
14. Severe chronic lung disease e.g., chronic obstructive pulmonary disease or interstitial lung disease where the forced expiratory volume in the first second (FEV1) is less than 50% and/or FEV1/forced vital capacity is less than 60%.
15. Hepatopulmonary syndrome.
16. Previous or current treatment with multiple infusions of albumin for therapeutic intent. \[Use of albumin infusion at the time of large volume paracentesis for circulatory support is allowed.\]
17. Significant untreated/unstable psychiatric disease.
18. Transjugular intrahepatic portosystemic shunt (TIPSS).
7. As judged by the Investigator, any evidence of intercurrent illness that is either life threatening or of clinical significance such that it might limit compliance with study procedures.
8. Current or planned use of immunomodulators or immunosuppressive medication; note: low doses of corticosteroids up to 10 mg/kg/day prednisone or equivalent are permitted, or inhaled steroids to manage asthma.
9. Received a gene or cell therapy at any time.
10. Current or planned use of a live attenuated vaccines four weeks or fewer prior to enrolment (and for 3 months after the last administered dose of RTX001).
11. Received any investigational product within the past 6 months, or five half-lives (whichever is longer) or participated in another investigational interventional study within 30 days prior to the screening visit.
12. Participants with a known hypersensitivity to dimethyl sulfoxide (DMSO).
13. Judgment by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
14. For female participants only - pregnant or breast-feeding or plans to become pregnant over the next year, or of childbearing potential and unwilling to comply with contraceptive requirements.
15. Alcohol misuse in the period between identification of the participant as potentially suitable for this study to Screening (Visit 1), defined as alcohol intake greater than three units/day for females and four units/day for males, or binge drinking (\>14 units/day) as determined by the Investigator. N.B. One unit is equivalent to 14 g of alcohol: a half-pint (\~240 mL) of beer, one glass (125 mL) of wine or one (25 mL) measure of spirits.
16. Intake of non-medically supervised drugs of abuse that are judged (by the Investigator) to be a high risk to the participants acute health or which makes the participant likely to be non-compliant with follow-up.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Resolution Therapeutics Limited
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Universitario Reina Sofía
Córdoba, , Spain
Hospital General Universitario Gregorio Marañon
Madrid, , Spain
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Universitario Virgen del Rocío
Seville, , Spain
Bristol Royal Infirmary
Bristol, , United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, , United Kingdom
Glasgow Royal Infirmary
Glasgow, , United Kingdom
Royal Liverpool University Hospital
Liverpool, , United Kingdom
King's College Hospital
London, , United Kingdom
St George's Hospital
London, , United Kingdom
St Mary's Hospital
London, , United Kingdom
Nottingham University Hospital
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Forbes S et al., Hepatology. AASLD Abstract #0095 (2024)
Brennan et al., Hepatology. AASLD Abstract #160 (2023) https://www.aasld.org/the-liver-meeting/open-label-parallel-group-phase-ii-randomised-controlled-trial-autologous
LBP-007 Beneficial effects of autologous macrophage therapy on clinical outcomes in patients with compensated cirrhosis: extended follow-up data from a randomized controlled phase 2 trial Brennan, Paul et al. Journal of Hepatology, Volume 80, S81 DOI: 10.1016/S0168-8278(24)00574-9
Moroni F, Dwyer BJ, Graham C, Pass C, Bailey L, Ritchie L, Mitchell D, Glover A, Laurie A, Doig S, Hargreaves E, Fraser AR, Turner ML, Campbell JDM, McGowan NWA, Barry J, Moore JK, Hayes PC, Leeming DJ, Nielsen MJ, Musa K, Fallowfield JA, Forbes SJ. Safety profile of autologous macrophage therapy for liver cirrhosis. Nat Med. 2019 Oct;25(10):1560-1565. doi: 10.1038/s41591-019-0599-8. Epub 2019 Oct 7.
Related Links
Access external resources that provide additional context or updates about the study.
The OPAL Study on ClinicalTrials.gov
British Liver Trust - The EMERALD Study
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-516288-10
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
RTX001-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.